We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Raptor Discontinues Development of Liver Drug
Raptor Pharmaceuticals says it does not plan to develop its liver drug, RP103, after it missed the primary endpoint in a Phase 2b study for nonalcoholic steatohepatitis in children.